Literature DB >> 8325762

Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma.

J C Whelchel1, S E Farah, I W McLean, M N Burnier.   

Abstract

PURPOSE: To investigate using immunohistochemistry the unusual finding that tumor infiltrating lymphocytes (TIL) in uveal melanomas are associated with a higher mortality rate.
METHODS: We performed immunohistochemistry for B and T lymphocytes on 80 uveal malignant melanomas, which previously had been reported to contain more than 100 TIL per 20 high-powered fields. In a second study of 90 patients, we counted the number of immunohistochemically stained T lymphocytes per 20 high-powered fields in uveal melanomas from 30 patients who survived at least 15 years after enucleation, from 30 patients who died with metastasis within 2 years, and from 30 patients who died with metastasis more than 10 years after enucleation.
RESULTS: T cells predominated in 73.8% of the 80 patients, and B cells were more prevalent in 13.8%. T cells were usually scattered, and B cells were usually in clumps. Post-enucleation 18-yr mortality from metastasis was 73% for patients with either T- or B-cell predominance of their TIL. The mortality rate was 32% for patients with few TIL. The patients who survived at least 15 yrs after enucleation had fewer T lymphocytes infiltrating their uveal melanomas than the two groups of patients who died with metastasis.
CONCLUSIONS: The pattern of the TIL was different for T and B cells in uveal melanomas. T-lymphocytic infiltration is associated with death due to metastasis.

Entities:  

Mesh:

Year:  1993        PMID: 8325762

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  26 in total

1.  Ocular tumors: Triumphs, challenges and controversies.

Authors:  Ralph C Eagle
Journal:  Saudi J Ophthalmol       Date:  2013-07

Review 2.  Uveal melanoma as a target for immune-therapy.

Authors:  Marc Oliva; Antonio J Rullan; Josep M Piulats
Journal:  Ann Transl Med       Date:  2016-05

3.  HLA expression in a primary uveal melanoma, its cell line, and four of its metastases.

Authors:  D J Blom; L R Schurmans; I De Waard-Siebinga; D De Wolff-Rouendaal; J E Keunen; M J Jager
Journal:  Br J Ophthalmol       Date:  1997-11       Impact factor: 4.638

Review 4.  Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.

Authors:  Kimberly M Komatsubara; Richard D Carvajal
Journal:  Curr Oncol Rep       Date:  2017-07       Impact factor: 5.075

5.  Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters.

Authors:  Lata Singh; Mithalesh Kumar Singh; Maria Cristina Kenney; Martine J Jager; Moshahid Alam Rizvi; Rachna Meel; Neiwete Lomi; Sameer Bakhshi; Seema Sen; Seema Kashyap
Journal:  Cancer Immunol Immunother       Date:  2020-11-02       Impact factor: 6.968

6.  HLA expression and tumor-infiltrating immune cells in uveal melanoma.

Authors:  I de Waard-Siebinga; C G Hilders; B E Hansen; J L van Delft; M J Jager
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-01       Impact factor: 3.117

7.  Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion.

Authors:  Peter W Chen; Jessamee K Mellon; Elizabeth Mayhew; Shixuan Wang; Yu Guang He; Nick Hogan; Jerry Y Niederkorn
Journal:  Exp Eye Res       Date:  2007-07-25       Impact factor: 3.467

Review 8.  Molecular pathology of uveal melanoma.

Authors:  S E Coupland; S L Lake; M Zeschnigk; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

Review 9.  The pathology of ocular cancer.

Authors:  R C Eagle
Journal:  Eye (Lond)       Date:  2012-11-16       Impact factor: 3.775

10.  Expression of vascular endothelial growth factor-A, matrix metalloproteinase-9, and extravascular matrix patterns and their correlations with clinicopathologic parameters in posterior uveal melanomas.

Authors:  Afsun Sahin; Hayyam Kiratli; Figen Soylemezoglu; Gaye Guler Tezel; Sevgul Bilgic; Osman Saracbasi
Journal:  Jpn J Ophthalmol       Date:  2007-10-05       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.